« Palestinians Use Bible As Toilet Paper While "News-Weak" And Other MSM Snooze | Main | Nutrition Gene Key In Regulating Immune System »
May 19, 2005
Cystatin C May Push Creatinine Off Risk Radar
Topics: Clinical PharmacologyA study reported in the New England Journal of Medicine affirms the important link between kidney function and cardiovascular health, and survival in the elderly. According to the director of the institute that funded the study, should these findings be confirmed in other studies, cystatin-C could be a useful prognostic tool for evaluating older people at risk for not only kidney disease, but also cardiovascular disease. Interestingly, the study suggests that serum levels of cystatin C correlate with risk of all causes mortality as well as risk of cardiac event.
The researchers measured creatinine and cystatin C in blood samples collected from 4,637 participants in the Cardiovascular Health Study, a community-based longitudinal study of people aged 65 or older at enrollment in 1989 and 1990.
Posted by Hyscience at May 19, 2005 9:32 AM
Articles Related to Clinical Pharmacology:
- Britain tests first Cannabis related medicine for rheumatoid arthritis - Nov 13, 2005
- Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma - May 26, 2005
- Cancer Treatment Success Stuns Scientists - May 16, 2005
- Antibody, cancer drug combo shows promise against breast tumors - May 16, 2005
- USC researchers determine mechanism of action of motexafin gadolinium (Xcytrin) - May 02, 2005
- Herceptin® Combined With Chemotherapy Improves Disease-Free Survival for Patients With Early-Stage Breast Cancer - Apr 26, 2005
- Selenium will have critical role in prostate cancer treatment - Fox Chase Cancer Center - Apr 21, 2005
- Traditional Medicine Derivatives Kill Cancer Cells - Apr 20, 2005
- Compound from Chinese medicine shows promise in head and neck cancer, U-M study finds - Apr 19, 2005
- Avastin (Bevacizumab, rhuMAb-VEGF) Plus Chemotherapy Appears to Produce Significant Benefit in First-Line Metastatic Breast Cancer - Apr 18, 2005
